Vaccine Approval Could Mark a Turning Point in CRE Price Discovery via NREI

Investors hoping to cash in on a COVID-19 pricing discounts may see opportunities slip away as emergency-use approval of the first vaccine against in the virus was granted to Pfizer and with availability expected to grow as other firms gain approvals in the coming weeks and months.

The coming widespread distribution of vaccines could very well prove to be the long-awaited light at the end of the tunnel for some struggling assets. Many buyers in the market have been hoping to negotiate at least some COVID-19 discount on pricing, even a slight five percent to 10 percent discount based on weaker rent growth. “I think there could still be some deals made in that range, but the combination of the vaccine outlook combined with more and more active liquidity in debt markets are going to make it more difficult to find those opportunities in the near term,” says David Bitner, head of Americas Capital Markets Research at Cushman & Wakefield.

Read more...Vaccine Approval Could Mark a Turning Point in CRE Price Discovery via NREI